Literature DB >> 33322437

Activation of the miR-371/372/373 miRNA Cluster Enhances Oncogenicity and Drug Resistance in Oral Carcinoma Cells.

Shu-Chun Lin1,2,3, Hsiao-Li Wu1, Li-Yin Yeh1, Cheng-Chieh Yang1,2,3, Shou-Yen Kao1,2,3, Kuo-Wei Chang1,2,3.   

Abstract

Oral squamous cell carcinoma (OSCC) is among the leading causes of cancer-associated deaths worldwide. Family members in miR-371/372/373 miRNA cluster, which is localized at human chromosome 19q13.4, are co-expressed in both human stem cells and malignancies. The individual miRNA in this cluster are also involved in modulating the pathogenesis of malignancies as either oncogenes or suppressors. The 19q13 region is frequently gained in head and neck cancers. High expression of miR-372 and miR-373 are survival predictors for OSCC. However, the role of the miR-371/372/373 cluster in oral carcinogenesis remains to be fully investigated. We use the clustered, regularly interspaced, short palindromic repeats (CRISPR)-Cas9 system to establish OSCC cell subclones that had the miR-371/372/373 cluster deleted. In addition, further subclones were established that had the promoter of this cluster deleted. Concordant silencing in SAS cells of miR-371/372/373 decreased oncogenic potential, increased cisplatin sensitivity, activated p53, and upregulated the expression of Bad and DKK1. We also employed the CRISPR/dCas9 synergistic activation mediator system, which allowed robust transcriptional activation of the whole miR-371/372/373 cistron. Upregulation of endogenous miR-371/372/372 expression increased both oncogenicity and drug resistance. These were accompanied by a slight activation of AKT, β-catenin, and Src. This study identifies the oncogenic role of the miR-371/372/373 cluster in OSCC. Using CRISPR based strategy can be a powerful paradigm that will provide mechanistic insights into miRNA cluster functionality, which will also likely help the development of targeting options for malignancies.

Entities:  

Keywords:  CRISPR; apoptosis; cancer; gene cluster; miR-371/372/373; promoter

Year:  2020        PMID: 33322437      PMCID: PMC7764723          DOI: 10.3390/ijms21249442

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  40 in total

Review 1.  A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology.

Authors:  Xiaoshu Xu; Lei S Qi
Journal:  J Mol Biol       Date:  2018-06-26       Impact factor: 5.469

2.  MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis.

Authors:  Rui-Qing Tian; Xing-Hua Wang; Li-Juan Hou; Wei-Hua Jia; Qian Yang; Yi-Xuan Li; Min Liu; Xin Li; Hua Tang
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

3.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.

Authors:  Chung-Ji Liu; Wilma Grace Shen; Shih-Yuan Peng; Hui-Wen Cheng; Shou-Yen Kao; Shu-Chun Lin; Kuo-Wei Chang
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

5.  Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.

Authors:  S Adi Harel; N Bossel Ben-Moshe; Y Aylon; D R Bublik; N Moskovits; G Toperoff; D Azaiza; F Biagoni; G Fuchs; S Wilder; A Hellman; G Blandino; E Domany; M Oren
Journal:  Cell Death Differ       Date:  2015-01-16       Impact factor: 15.828

6.  β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway.

Authors:  A-D Zhou; L-T Diao; H Xu; Z-D Xiao; J-H Li; H Zhou; L-H Qu
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

7.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.

Authors:  Silvana Konermann; Mark D Brigham; Alexandro E Trevino; Julia Joung; Omar O Abudayyeh; Clea Barcena; Patrick D Hsu; Naomi Habib; Jonathan S Gootenberg; Hiroshi Nishimasu; Osamu Nureki; Feng Zhang
Journal:  Nature       Date:  2014-12-10       Impact factor: 49.962

8.  microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells.

Authors:  Xiangjie Kong; Xiaoqiang Qian; Liujian Duan; Hailong Liu; Yingjian Zhu; Jun Qi
Journal:  DNA Cell Biol       Date:  2016-09-27       Impact factor: 3.311

9.  The miR-371∼373 Cluster Represses Colon Cancer Initiation and Metastatic Colonization by Inhibiting the TGFBR2/ID1 Signaling Axis.

Authors:  Pit Ullmann; Fabien Rodriguez; Martine Schmitz; Steffen K Meurer; Komal Qureshi-Baig; Paul Felten; Aurélien Ginolhac; Laurent Antunes; Sonia Frasquilho; Nikolaus Zügel; Ralf Weiskirchen; Serge Haan; Elisabeth Letellier
Journal:  Cancer Res       Date:  2018-05-10       Impact factor: 12.701

Review 10.  Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.

Authors:  Takashi Takeuchi; Hiromichi Kawasaki; Amalia Luce; Alessia Maria Cossu; Gabriella Misso; Marianna Scrima; Marco Bocchetti; Filippo Ricciardiello; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

View more
  9 in total

1.  Aberrant miR-10b, miR-372, and miR-375 expression in the cytobrushed samples from oral potentially malignant disorders.

Authors:  Hsi-Feng Tu; Kuo-Wei Chang; Shu-Chun Lin; Wan-Wen Hung; Si-Hua Ji; Hsiao-Li Wu; Chung-Ji Liu
Journal:  J Dent Sci       Date:  2021-07-30       Impact factor: 3.719

Review 2.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

3.  Oral Fibrosis and Oral Cancer: From Molecular Targets to Therapeutics.

Authors:  Pei-Ling Hsieh; Cheng-Chia Yu
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 4.  Aberrant Expression of microRNA Clusters in Head and Neck Cancer Development and Progression: Current and Future Translational Impacts.

Authors:  Li-Jie Li; Wei-Min Chang; Michael Hsiao
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-27

Review 5.  The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.

Authors:  Jing Zuo; Zhe Zhang; Maomao Li; Yun Yang; Bohao Zheng; Ping Wang; Canhua Huang; Shengtao Zhou
Journal:  Mol Cancer       Date:  2022-01-26       Impact factor: 27.401

Review 6.  Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy.

Authors:  Dimitri Papukashvili; Nino Rcheulishvili; Cong Liu; Fengfei Xie; Deependra Tyagi; Yunjiao He; Peng George Wang
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

7.  miR-31-NUMB Cascade Modulates Monocarboxylate Transporters to Increase Oncogenicity and Lactate Production of Oral Carcinoma Cells.

Authors:  Chung-Hsien Chou; Chun-Yu Fan Chiang; Cheng-Chieh Yang; Ying-Chieh Liu; Sih-Rou Chang; Kuo-Wei Chang; Shu-Chun Lin
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

Review 8.  Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer.

Authors:  Karen Yamaguchi; Tomofumi Yamamoto; Junichiro Chikuda; Tatsuo Shirota; Yusuke Yamamoto
Journal:  Biomolecules       Date:  2022-02-09

9.  CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology.

Authors:  Monika Drobna-Śledzińska; Natalia Maćkowska-Maślak; Roman Jaksik; Paulina Dąbek; Michał Witt; Małgorzata Dawidowska
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.